Review highlights non-coding RNAs as potential biomarkers and therapeutic targets in non-small cell lung cancer, indicating their role in Hippo signaling.
The most common type of cancer and one with a high death rate is lung cancer, especially non-small cell lung cancer (NSCLC), which is mostly brought on by medication resistance, metastasis, and delayed diagnosis. The discovery of non-coding RNAs (ncRNAs), such as circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), has revealed their vital involvement in the pathophysiology of lung cancer by controlling important cellular processes. The Hippo signaling pathway is one of the critical routes impacted by non-coding RNAs. It is involved in tumor suppression, apoptosis, and cell proliferation. The interaction between ncRNAs and the Hippo pathway in lung cancer is reviewed in this review, with an emphasis on the potential of these molecules as therapeutic targets as well as diagnostic and prognostic biomarkers.
No takes yet. Share an insight, caveat, or question.
Joulani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: